C. difficile Infection Diagnosis and Management

Diagnostic Considerations

• The PCR/NAAT test detects the genetic material of C. difficile bacteria with very high sensitivity (93-94%), but it cannot distinguish between active infection and harmless colonization, according to the Infectious Diseases Society of America 1, 2
• Approximately 44-55% of patients who test positive by PCR will be negative for toxins, representing colonization rather than true infection, as reported by the Clinical Infectious Diseases journal 3
• Patients who are both gene-positive AND toxin-positive have significantly worse outcomes: 7.6% complication rate, 8.4% mortality, and longer duration of diarrhea, as stated by the Infectious Diseases Society of America 2, 3
• Patients who are gene-positive but toxin-negative have minimal complications: 0% complication rate in the largest study, 0.6% mortality, and outcomes similar to patients without C. difficile at all, according to the Clinical Infectious Diseases journal 3

Clinical Assessment and Management

• Diarrhea severity, defined as ≥3 unformed stools in 24 hours that conform to the container shape, is a factor that suggests true infection, as recommended by the Infectious Diseases Society of America 1, 4
• Recent antibiotic exposure is a strong risk factor for true CDI, as reported by the Clinical Infectious Diseases journal 2, 4
• For patients with severe illness (high fever, significant leukocytosis, rising creatinine, or severe diarrhea), consider empiric treatment with oral vancomycin 125 mg four times daily while awaiting toxin results, as suggested by the Critical Care Medicine journal 5
• Severe illness warrants treatment even before confirmatory testing is complete, according to the Critical Care Medicine journal 5

Testing and Treatment Considerations

• Do not repeat testing within 7 days of the initial test during the same diarrheal episode—this increases false-positive results and has only 2% diagnostic yield, as recommended by the Infectious Diseases Society of America 1, 4
• Higher risk for complications and recurrence is associated with positive toxin results, as reported by the Clinical Infectious Diseases journal 2, 3

Management of Positive C. difficile Toxin Test Results

Diagnostic Interpretation and Clinical Significance

• Patients who are toxin-positive have significantly higher rates of complications and longer duration of diarrhea compared to those who are PCR-positive but toxin-negative 6, 7
• The presence of toxins correlates with true clinical disease requiring antimicrobial intervention 6, 8
• Toxin-positive patients represent true infections rather than colonization, which is an important distinction for clinical management 7, 9

Diagnostic Testing Approaches

• Multi-step algorithms provide better clinical correlation than single tests 6, 10
• Nucleic acid amplification tests (NAATs) alone have high sensitivity but may detect colonization rather than active infection 9, 10
• A positive likelihood ratio (LR+) >10 for toxin tests indicates high probability that disease is present when the test is positive 10

Treatment Algorithm

• Initial assessment of severity should consider factors such as white blood cell count and serum creatinine levels 9

Important Clinical Considerations

• Do not perform test of cure as >60% of patients may remain C. difficile positive even after successful treatment 11
• Implement antimicrobial stewardship to reduce risk of recurrence 11

Contrast with PCR-Positive/Toxin-Negative Results

• Patients who are PCR-positive but toxin-negative should be considered "excretors" who may present an infection control risk but generally do not require treatment 6, 11
• Clinical assessment is crucial in PCR-positive/toxin-negative cases to rule out alternative causes of diarrhea 11

Follow-up

• Consider discontinuing unnecessary proton pump inhibitors to reduce recurrence risk 11

C. difficile Diagnosis and Management

Introduction to C. difficile Testing

• The IDSA/SHEA 2018 guidelines recommend using NAAT to arbitrate discordant results in a three-step algorithm: GDH plus toxin, arbitrated by NAAT when results are discordant 12
• This approach provides results for approximately 85-92% of samples on the day of receipt, with only 8-15% requiring further testing 13

PCR Characteristics and Clinical Interpretation

• PCR/NAAT detects C. difficile genetic material with very high sensitivity, and is most appropriately used as part of a multi-step algorithm rather than as a stand-alone test 12
• Do NOT use PCR alone as a stand-alone test in endemic settings due to low positive predictive value 12, 14

Testing and Management Algorithms

• If GDH positive/toxin negative: Perform PCR/NAAT for arbitration 12
• In epidemic settings, multiple sample submission may be warranted due to lower negative predictive values 13

Diagnostic Approach for C. difficile Infection

Testing Algorithm

• The Infectious Diseases Society of America recommends using a multistep testing algorithm rather than any single test alone, with the specific approach depending on whether your institution has pre-agreed criteria for stool submission 15, 16, 17
• When pre-agreed institutional criteria exist for stool submission, the American College of Gastroenterology suggests using NAAT alone or a multistep algorithm (GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin) to maximize sensitivity 15, 17
• In the absence of pre-agreed institutional criteria, the Infectious Diseases Society of America recommends using a stool toxin test as part of a multistep algorithm (GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin) rather than NAAT alone 16, 17

Test Selection and Interpretation

• The American College of Gastroenterology recommends performing GDH (glutamate dehydrogenase) immunoassay as the first screening test, which detects the common antigen present in all C. difficile strains with high sensitivity 16, 18
• If GDH positive, the Infectious Diseases Society of America suggests performing toxin A/B enzyme immunoassay (EIA) with sensitivity in the upper range reported in the literature 16, 17

Patient Selection for Testing

• The Infectious Diseases Society of America recommends only testing unformed stool samples from symptomatic patients meeting specific criteria, including ≥3 unformed stools in 24 hours, no laxative use within 48 hours, and no obvious alternative explanation for diarrhea 16, 19
• The American Academy of Pediatrics suggests not testing infants ≤12 months of age due to high prevalence of asymptomatic carriage 15, 16

Special Considerations

• The Infectious Diseases Society of America recommends against repeat testing within 7 days during the same diarrheal episode, as it has only 2% diagnostic yield and increases false positives 16, 17
• The American College of Gastroenterology suggests not testing asymptomatic patients except for epidemiological studies 16, 17